News for Personalis, Inc. (PSNL)

Personalis offers promising ultra-sensitive MRD genomic tests, but faces intense competition that threatens growth and profitability. See why PSNL stock is a Hold.

[url="]Personalis, Inc[/url]. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA ph

Personalis (PSNL) has unveiled significant findings from its CALLA phase 3 study, revealing that the NeXT Personal circulating tumor DNA blood test can detect t

Personalis, Inc.

Personalis (PSNL) has unveiled promising findings from its PREDICT DNA and SCANDARE studies, emphasizing the effectiveness of its NeXT Personal ctDNA blood test

[url="]Personalis, Inc[/url]. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of

Personalis, Inc. (PSNL) to present latest data at ASCO Annual Meeting in Chicago, Illinois. Presentations focus on NeXT Personal® ultrasensitive ctDNA

Life Science & Diagnostic Tools Analyst, Massaro, is set to engage with the management team of a company via a virtual meeting scheduled for December 8. This ev

Guggenheim has begun its analysis of Personalis (PSNL), issuing a Buy rating and setting a price target of $6 for the stock. This move indicates Guggenheim's po

ARK ETFs sold 376,874 Palantir (PLTR) shares for $46.65 million, continuing a week-long reduction, while investing $10.45 million in 237,374 Guardant Health (GH) shares, signaling a shift from data analytics to precision oncology. Significant purchases included $10.17 million for 283,186 Twist Bioscience (TWST) shares and $8.75 million for 55,623 Natera…

On May 7, 2025, a notable development was reported regarding Personalis (PSNL). The well-regarded financial services firm, HC Wainwright & Co., has maintained i

H.C. Wainwright has revised its price target for Personalis (PSNL), boosting it from $8 to $9, while maintaining a Buy rating on the stock. This decision comes

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NPSNL.OQ - Personalis IncQ1 2025 Personalis Inc Earnings CallMay 06, 2025 / 09:00PM GMT =======

Summary: Personalis, Inc. (PSNL) sees a significant 650% surge in molecular test usage, contributing to Q1 2025 revenue of $20.6 million.Analysts suggest a prom

Gain insights into Personalis, Inc.'s Q1 2025 performance, including a 52% test volume increase, 39% revenue growth, and progress in Medicare reimbursement...

Personalis, Inc. (NASDAQ:PSNL) Q1 2025 Earnings Conference Call May 6, 2025 5:00 PM ETCompany ParticipantsCaroline Corner - Investor RelationsChristopher...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended Mar

Personalized Medicine Inc. (PSNL) anticipates generating revenue from a variety of sources. The company expects income from pharmaceutical tests and services, a

Personalis Inc (PSNL) is set to release its Q1 2025 earnings on May 6, 2025. The consensus estimate for Q1 2025 revenue is $17.42 million, and the earnings are